Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule’s third-party manufacturer.
GSK acquired global rights to Brexafemme, a novel antifungal from Scynexis that is approved for treating vaginal yeast infections. The deal also gives GSK the chance to commercialize the drug in other indications.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
Amplyx Pharmaceuticals brings Pfizer a clinical-stage antifungal candidate with a novel mechanism of action. The pharmaceutical giant is trying to build its antifungal product lineup, which is currently led by a drug that has lost patent protection.
Cidara Therapeutics has emerged from relative obscurity with a new name, a new antifungal drug platform and a $32 million Series A financing round to help bring it to clinical trial over the next 18 months. The financing will help Cidara advance candidates from its Cloudbreak targeted immunotherapy platform, and bring its novel antifungal drug […]